These results suggest that antagonizing Nsp1 function by interfering with its ability to bind NXF1 represents a potential means to inhibit SARS-CoV-2 replication, and thus the Nsp1-NXF1 complex is a potential target for the development of a therapeutic strategy for the treatment of COVID-19. This evidence concerns the gene NXF1 and COVID-19.